OSR Holdings, Inc. (OSRH)

NCM – Real Time Price. Currency in USD

0.46

+0.02 (5.57%)

At close: Mar 27, 2026, 4:00 PM EDT

0.44

-0.02 (-4.33%)

After-hours: Mar 27, 2026, 7:56 PM EDT

27.03.2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

NEW YORK CITY, NY / ACCESS Newswire / March 27, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00. The flash report highlights recent developments related to the Company's non-invasive glucose monitoring technology (Woori IO), including increasing global interest in potential licensing and distribution opportunities.

23.03.2026

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

BELLEVUE, WA / ACCESS Newswire / March 23, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM Europe AG for the global licensing of its lead oncology asset VXM01. The revised structure is designed to improve capital efficiency and shift economic benefits directly to the parent company, OSR Holdings and its shareholders.

19.03.2026

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical distribution enterprise of China.

05.03.2026

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

BELLEVUE, WASHINGTON / ACCESS Newswire / March 5, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing innovative biomedical technologies, today announced that it has received written notification from The Nasdaq Stock Market LLC granting the Company an additional 180-calendar-day extension to regain compliance with Nasdaq Listing Rule 5550(a)(2), the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market. The extension provides the Company until August 31, 2026, to satisfy the rule by achieving a closing bid price of at least $1.00 per share for ten consecutive business days.

02.02.2026

CEO Statement to Shareholders

BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value Creation As the compliance deadline under the minimum bid requirement of NASDAQ approaches, we recognize that market volatility and uncertainty can weigh on investor sentiment. Periods like this often test confidence, particularly for innovation-driven companies that are building long-term value rather than optimizing for short-term optics.

27.01.2026

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment by Woori IO's historical shareholders, and the initiation of a strategic review regarding a potential combination of its medical device subsidiaries. Woori IO Acquisition Closed OSRH confirmed that the previously announced acquisition of Woori IO and the related share exchange transaction have been formally completed in Korea, effective January 26, 2026.

22.01.2026

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.

Videos

No Data

There is no data to display

Press releases

27.03.2026

OSR Holdings, Inc. (OSRH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

OSR Holdings, Inc. (OSRH)

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

CEO Statement to Shareholders

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Videos

No Data

Press releases

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

CEO Statement to Shareholders

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Videos

No Data

Press releases

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum